Medication Guide App

Generic Renagel Availability

Renagel is a brand name of sevelamer, approved by the FDA in the following formulation(s):

RENAGEL (sevelamer hydrochloride - tablet; oral)

  • Manufacturer: GENZYME
    Approval date: July 12, 2000
    Strength(s): 400MG, 800MG [RLD]

Has a generic version of Renagel been approved?

No. There is currently no therapeutically equivalent version of Renagel available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Renagel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Phosphate-binding polymers for oral administration
    Patent 5,496,545
    Issued: March 5, 1996
    Inventor(s): Holmes-Farley; Stephen R. & Mandeville, III; W. Harry & Whitesides; George M.
    Assignee(s): GelTex Pharmaceuticals, Inc.
    Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
    Patent expiration dates:
    • August 11, 2013
      ✓ 
      Patent use: PHOSPHATE BINDING
  • Phosphate-binding polymers for oral administration
    Patent 5,667,775
    Issued: September 16, 1997
    Inventor(s): Holmes-Farley; Stephen Randall & Mandeville, III; W. Harry & Whitesides; George M.
    Assignee(s): GelTex Pharmaceuticals, Inc.
    Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
    Patent expiration dates:
    • September 16, 2014
      ✓ 
      Patent use: PHOSPHATE BINDING
  • Method of making phosphate-binding polymers for oral administration
    Patent 6,509,013
    Issued: January 21, 2003
    Inventor(s): Stephen Randall; Holmes-Farley & W. Harry; Mandeville, III & George M.; Whitesides
    Assignee(s): GelTex Pharmaceuticals, Inc.
    Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
    Patent expiration dates:
    • August 11, 2013
  • Direct compression polymer tablet core
    Patent 6,733,780
    Issued: May 11, 2004
    Inventor(s): Joseph; Tyler & John S.; Petersen
    Assignee(s): Genzyme Corporation
    The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin. The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.
    Patent expiration dates:
    • October 18, 2020
      ✓ 
      Drug product
  • Phosphate-binding polymers for oral administration
    Patent 7,014,846
    Issued: March 21, 2006
    Inventor(s): Holmes-Farley; Stephen Randall & Manderville, III; W. Harry & Whitesides; George M.
    Assignee(s): Genzyme Corporation
    Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
    Patent expiration dates:
    • August 11, 2013
      ✓ 
      Patent use: PHOSPHATE BINDING
      ✓ 
      Drug product
  • Phosphate-binding polymers for oral administration
    Patent 7,459,151
    Issued: December 2, 2008
    Inventor(s): Holmes-Farley; Stephen Randall & Mandeville, III; W. Harry & Whitesides; George M.
    Assignee(s): Genzyme Corporation
    Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
    Patent expiration dates:
    • August 11, 2013
      ✓ 
      Patent use: PHOSPHATE BINDING

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Advertisement
Close

Recommended

(web6)